All posts by livingandlearning2015@gmail.com

MannKind Announces Direct Purchase Insulin Program Providing Afrezza® for as low as $4 a Day

https://globenewswire.com/news-release/2019/01/16/1700952/0/en/MannKind-Announces-Direct-Purchase-Insulin-Program-Providing-Afrezza-for-as-low-as-4-a-Day.html

WESTLAKE VILLAGE, Calif., Jan. 16, 2019 (GLOBE NEWSWIRE) — MannKind Corporation (Nasdaq:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, today announced a direct purchase program to help those with diabetes obtain the company’s inhaled insulin, Afrezza, for as little as $4 a day.  Afrezza (insulin human) Inhalation Powder is a rapid-acting inhaled insulin indicated to improve glycemic control in adult patients with diabetes mellitus.

“It is important for MannKind to help those whose lives depend on insulin, and, unfortunately, over 65,000 uninsured or under-insured patients today must pay cash for their insulin each month, typically at the pharmacy counter at prices that reflect the costs of the pharmaceutical distribution chain,” said Michael Castagna, Chief Executive Officer of MannKind. “Our new Afrezza Patient Direct Program enables us to streamline the numerous costs and inefficiencies that exist in today’s healthcare system, so we can pass along the savings directly for these patients. We want to be part of the solution for the future of healthcare and healthy living.”

Participation in this innovative cash program, which is available to all eligible patients with a valid prescription, is simple. The first 1,000 people to register at www.insulinsavings.com will gain access to introductory pricing for the Afrezza Patient Direct Program, giving them the opportunity to purchase Afrezza for as little as $4 a day for the first twelve months. All participants who sign up for the program will gain access to attractive cash pricing for Afrezza.

Continue reading MannKind Announces Direct Purchase Insulin Program Providing Afrezza® for as low as $4 a Day

Please follow and like us:

Afrezza: Tips from Users on Titration (Dosage and Timing)

Get Support from other Afrezza Users

If you are just starting to use Afrezza, you can post questions (such as titration or any other related issues) to the Afrezza User Facebook Group.  People there are very helpful and responsive. Fudiabetes.org is a new forum run by a group of Afrezza-friendly people.  Quite a few active Afrezza users post on that forum.  Twitter is another platform where active Afrezza users post their results and share their experience quite frequently.

Continue reading Afrezza: Tips from Users on Titration (Dosage and Timing)

Please follow and like us:

Afrezza: Medical Publications/Discussions

Improved Postprandial Glucose with Inhaled Technosphere Insulin Compared with Insulin Aspart in Patients with Type 1 Diabetes on Multiple Daily Injections: The STAT Study

Journal of Diabetes Science and Technology  (Ahead of Print)

Improved Postprandial Glucose with Inhaled Technosphere Insulin Compared with Insulin Aspart in Patients with Type 1 Diabetes on Multiple Daily Injections: The STAT Study

Abstract

Background: The majority of therapies have generally targeted fasting glucose control, and current mealtime insulin therapies have longer time action profiles than that of endogenously secreted insulin. The primary purpose of this study was to assess both glucose time-in-range (TIR: 70–180 mg/dL) and postprandial glucose excursions (PPGE) in 1–4 h using a real-time continuous glucose monitor (CGM) with Technosphere insulin (TI) versus insulin aspart in patients with type 1 diabetes (T1DM) on multiple daily injections (MDI).

Research Design and Methods: This pilot, investigator-led, collaborative, open-label, multicenter, clinical research trial enrolled 60 patients with T1DM with HbA1c levels ≥6.5% and ≤10%. Individuals were randomized to treatment with titrated TI (n = 26) or titrated insulin aspart (n = 34), stratified by baseline HbA1c levels (≤8% or >8%). All were required to wear a real-time CGM throughout the trial. All patients in the TI group were advised to take supplemental inhalations at 1 and 2 h after meals if indicated based on postprandial glucose (PPG) values. The coprimary outcomes were assessed both in the full intent-to-treat population and in those individuals randomized to TI who were compliant with supplemental doses ≥90% of the time (n = 15). The CGM data were analyzed using linear regression models.

Results: Overall, those treated with TI versus aspart achieved comparable TIR, but less time spent in hypoglycemia (<60 and <50 mg/dL, both P < 0.05). In the TI-compliant group (n = 15), TIR was significantly greater (62.5% ± 2.6% vs. 53.8% ± 1.7%, P = 0.009) and time in hyperglycemia >180 mg/dL was lower (34.2% ± 2.7% vs. 41.0% ± 1.7%, P = 0.045) as compared with the aspart group. PPG was also significantly lower in the TI cohort at 60 and 90 min postmeal, and PPGE were lower in the TI-compliant group as compared with the aspart group over 1–4-h postmeal (P < 0.05). In addition, there was weight gain in the aspart group compared with weight loss in the TI group (P = 0.006) despite higher prandial TI insulin dose.

Conclusions: We conclude that using TI appropriately at mealtimes with supplemental dosing improves prandial glucose (TIR and 1–4 h) control without any increase in time in hypoglycemia or weight gain in patients with T1DM on MDI. The study results support a larger study using a treat-to-target design to confirm these findings.  Continue reading Afrezza: Medical Publications/Discussions

Please follow and like us:

Afrezza: Correcting a High BG

Continue reading Afrezza: Correcting a High BG

Please follow and like us:

A1Cs of Afrezza Users

Continue reading A1Cs of Afrezza Users

Please follow and like us:

Afrezza: Less Hypos

Continue reading Afrezza: Less Hypos

Please follow and like us:

Afrezza: Pizza and Other Foods

Continue reading Afrezza: Pizza and Other Foods

Please follow and like us: